Phaseline

Companies › Amyloid Solution

Amyloid Solution: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AS-S603
Small molecule targeting amyloid-beta and tau aggregates
APP, MAPTPhase 1HealthyDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06786676AS-S603Phase 1HealthyNeurologyDec 2026

Targets

APP (1) MAPT (1)

Companies with the same targets

Roche Alnylam Pharmaceuticals Nuravax Eli Lilly Eisai Acumen Pharmaceuticals JYAMS PET Research & Development HTA Eli Radiopharma Bristol-Myers Squibb

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.